Contrasting Guided Therapeutics (GTHP) and Its Peers

Guided Therapeutics (OTCMKTS:GTHP) is one of 74 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its competitors? We will compare Guided Therapeutics to related companies based on the strength of its profitability, earnings, analyst recommendations, institutional ownership, valuation, risk and dividends.

Institutional & Insider Ownership

9.7% of Guided Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Electromedical equipment” companies are held by institutional investors. 66.8% of Guided Therapeutics shares are held by insiders. Comparatively, 15.0% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Guided Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-331.31%	-92.24%	-30.04%

Earnings & Valuation

This table compares Guided Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-5.33
Guided Therapeutics Competitors	$1.00 billion	$85.30 million	5.74

Guided Therapeutics’ competitors have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Guided Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ competitors have a beta of 17.00, meaning that their average share price is 1,600% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Guided Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	270	802	2016	109	2.61

As a group, “Electromedical equipment” companies have a potential upside of 3,305.07%. Given Guided Therapeutics’ competitors higher possible upside, analysts plainly believe Guided Therapeutics has less favorable growth aspects than its competitors.

Summary

Guided Therapeutics competitors beat Guided Therapeutics on 7 of the 10 factors compared.

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.